A Prospective, Open-Label, Controlled Multicenter Trial to Assess the Efficacy and Safety of an Induction Regimen of Cyclosporine Micro Emulsion, Enteric-Coated Mycophenolate Sodium (EC-MPS) and Corticosteroids, Followed by Administration of Everolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS), With Either the Withdrawal of Cyclosporine Micro Emulsion or Corticosteroids in de Novo Kidney Transplant Recipients.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Basiliximab; Ciclosporin; Everolimus; Mycophenolate sodium; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms SOCRATES
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 Aug 2013 Biomarkers information updated
- 13 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.